Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

This study is testing a combination of two drugs — cirtuvivint (a WNT pathway inhibitor) and olaparib (a PARP inhibitor) — for women with ovarian cancer that has a BRCA gene mutation or homologous recombination deficiency, and whose cancer has become resistant to platinum-based chemotherapy. **You may be eligible if...** - You are a woman aged 18 or older - You have high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube cancer - Your cancer is platinum-resistant (progressed less than 6 months after your last platinum treatment) - You have a BRCA gene mutation or evidence of homologous recombination deficiency (HRD) - You have at least one prior platinum-based chemotherapy - You have measurable disease on imaging and a general health score (ECOG) of 0–2 **You may NOT be eligible if...** - You have a clear cell, mucinous, or low-grade ovarian tumor - Your cancer is platinum-refractory (progressed during or within 4 weeks of platinum treatment) - You have received chemotherapy or radiation in the past 3 weeks - You have signs of myelodysplastic syndrome or acute myeloid leukemia Talk to your doctor to see if this trial is right for you.